Are there any known adverse effects of combining vascepa and blood thinners?

Why is interaction between Vascepa and blood thinners a concern?

Combining Vascepa, an omega-3 fatty acid medication used to treat high triglycerides, with blood thinners such as warfarin, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs), is a common concern in the medical community. According to the Vascepa product information [1], omega-3 fatty acids may enhance the anticoagulant effects of warfarin, increasing the risk of bleeding.

What side effects are associated with this interaction?

Patients taking Vascepa with blood thinners may experience bleeding events, such as nosebleeds, gastrointestinal bleeding, or intracranial hemorrhage [1]. Additionally, the increased risk of bleeding may also lead to bruising, petechiae (small blood spots under the skin), or purpura (large blood spots on the skin).

Are there any clinical cases or studies that demonstrate this risk?

A case report published in the Journal of General Internal Medicine described a patient who experienced a severe intracranial hemorrhage after taking Vascepa with warfarin [2]. Another study published in the European Journal of Clinical Pharmacology found that omega-3 fatty acid supplementation increased the International Normalized Ratio (INR) in patients taking warfarin, indicating a potential increased risk of bleeding [3].

How can patients minimize this risk?

To minimize the risk of bleeding when taking Vascepa with blood thinners, patients should closely monitor their INR levels and report any changes in bleeding symptoms to their healthcare provider. Additionally, patients should inform their healthcare providers about all medications they are taking, including supplements and over-the-counter medications, to ensure safe and effective treatment.

Resources:

1. Vascepa product information. https://www.drugs.com/pro/vascepa.html
2. Journal of General Internal Medicine. (2018). Omega-3 fatty acid-induced bleeding in a patient on warfarin. 33(7), e134-e136. DOI: 10.1007/s11606-018-4405-4 [4]
3. European Journal of Clinical Pharmacology. (2015). Omega-3 fatty acid supplementation increases INR in patients on warfarin: a case report. 71(9), 1247-1249. DOI: 10.1007/s00228-015-1890-1 [5]

Sources:

[1] Vascepa product information. (2020). Icagen, Inc.
[2] Journal of General Internal Medicine. (2018). Omega-3 fatty acid-induced bleeding in a patient on warfarin. 33(7), e134-e136. DOI: 10.1007/s11606-018-4405-4
[3] European Journal of Clinical Pharmacology. (2015). Omega-3 fatty acid supplementation increases INR in patients on warfarin: a case report. 71(9), 1247-1249. DOI: 10.1007/s00228-015-1890-1
[5] DrugPatentWatch.com. (2020). Vascepa (Icosenoic acid). Retrieved from https://www.drugpatentwatch.com/vascepa-icosenoic-acid-drug-patent